相关实验视频

Updated: Jul 15, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

在SARS-CoV-2患者中铁平氨酸异形度的年龄和性别相关差异

Sarah Allegra¹, Francesco Chiara¹, Marina Zanatta¹

¹Laboratory of Clinical Pharmacology "Franco Ghezzo", Department of Clinical and Biological Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10124 Orbassano, TO, Italy.

Life (Basel, Switzerland)

|September 28, 2023

概括

这项研究分析了SARS-CoV-2患者的提科普拉宁水平,发现基于年龄和性别的差异. 治疗药物监测可以改善感染管理,特别是对于新型病毒.

科学领域:

药理学药理学是指药理学的学科.
传染性疾病传染性疾病
临床化学临床化学

背景情况:

泰科普拉宁是一种糖类抗生素,在体外表现出对SARS-CoV-2的活性.
了解SARS-CoV-2患者中提科普拉宁的药理动力学对于有效治疗至关重要.

研究的目的:

在成人和儿科SARS-CoV-2患者中评估teicoplanin及其成分水平.
为了评估性别和年龄对提科普拉宁分析物度的影响.
为了识别SARS-CoV-2感染个体中存在的特定teicoplanin异型.

主要方法:

在成人和儿科SARS-CoV-2患者队列中分析泰科普拉宁及其异型.
在分析水平上对人口因素 (性别,年龄) 的评估.
性别之间的C反应蛋白,AST,ALT和白细胞水平的比较.

主要成果:

在儿童和成人患者中,甲基氨酸异型A2-2_3始终存在.
异形A2-4_5始终存在于成年男性和所有儿科患者中.
与男性相比,儿科女性的平均同位素度 (A3-1除外) 高于男性,而成年男性的水平高于成年女性.
基于性别的差异观察到AST,ALT,白细胞 (女性更高),C反应蛋白 (男性更高).

结论:

这是第一个详细介绍不同年龄组和性别的SARS-CoV-2患者teicoplanin异型水平的研究.
观察到的变化表明,治疗药物监测对优化SARS-CoV-2感染中的提科普拉宁治疗具有潜在的益处.
需要对更大的队列进行进一步的研究,以证实这些发现并指导临床实践.

关键词:

在这里,我们可以看到COVID COVID COVID.这是Targocidcid.性别性别性别性别性别儿科儿科儿科儿科在性爱中,性爱是性爱.

更多相关视频

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Published on: September 22, 2023

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

相关概念视频

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Time Course of Drug Effect

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...

Drug Concentration Versus Time Correlation

Drug Concentration Versus Time Correlation

The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...